US EditionTrump turns over new leaf in GOP drug policy with marijuana, psychedelics orders
The orders would move marijuana to Schedule III and give three psychedelic drug developers expedited FDA review vouchers, officials said.
- On Thursday, Acting Attorney General Todd Blanche signed an order reclassifying state-licensed medical marijuana to Schedule III, implementing President Donald Trump's April 18 executive order to accelerate psychedelic medicine research.
- The shift reflects influence from the 'Make America Healthy Again' movement and podcaster Joe Rogan, who texted Trump about ibogaine research, prompting focus on 'medicines of healing' for veterans with PTSD.
- FDA Commissioner Marty Makary announced three Commissioner's National Priority Vouchers for qualifying compounds, while the order allocates at least $50 million through ARPA-H to support state-level psychedelic research initiatives.
- Neither action legalizes recreational cannabis, which remains Schedule I; Senator Tom Cotton warned modern marijuana is 'much more potent than just ten or twenty years ago,' calling the change a 'step in the wrong direction.'
- Uncertainty remains before 2027 regarding whether the administration's rescheduling and expedited psychedelic reviews will succeed, as critics note the simultaneous cuts to harm-reduction infrastructure undermine the stated health agenda.
14 Articles
14 Articles
Donald Trump’s administration gave one of the most relevant turns in decades on drug policy in that country. According to El País, the Department of Justice decided to reclassify marijuana, taking it from the group of the most dangerous substances to a less restrictive category within federal legislation. The measure was executed by the interim attorney general, Todd Blanche, and fulfills a previous promise from the president. In concrete terms,…
Broad Wording in Trump Admin's Psychedelic Push Could Endanger Most Vulnerable Mentally Ill
President Donald Trump’s new executive order on psychedelics is being sold as a compassionate breakthrough for Americans suffering from serious mental illness. But for families living with schizophrenia, psychosis, and […] The post Broad Wording in Trump Admin's Psychedelic Push Could Endanger Most Vulnerable Mentally Ill appeared first on The Western Journal.
Trump Moves to Reschedule Pot, Fast-Track Psychedelics
The Justice Department moved Thursday to immediately reclassify state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act, acting on a December executive order from President Donald Trump, while the administration separately fast-tracked federal review of psychedelic drugs, including psilocybin and ibogaine, as potential treatments for mental illness.
Trump turns over new leaf in GOP drug policy with marijuana, psychedelics orders
The Trump administration’s moves on marijuana and psychedelics signal the start of a new era in Republican drug policy. The orders to fast-track reviews of psychedelic drugs and reschedule medical marijuana are a far cry from the party of “just say no” and former Republican President Richard Nixon’s war on drugs. “Regardless of what one…
Coverage Details
Bias Distribution
- 59% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
